SUMMARY The efficacy of cyclosporin in a double blind, placebo controlled trial of four months' duration has previously been reported by us. To assess the benefit-to-risk ratio of cyclosporin this study was followed by a one year open trial including 49 of the previous 52 patients. Cyclosporin was given at an initial dosage of 5 mg/kg/day and then modulated on the basis of efficacy and renal toxicity. During the study the drug had to be discontinued in 32 patients: because of inefficacy in 10, side effects in 11, both in nine, and in two because of unrelated events. The significant clinical improvement noted at four months persisted through one year in the 17 patients who continued to receive treatment. Nephrotoxicity of the drug (24 patients) required constant and close monitoring as well as modulation of daily drug dosage during the trial. This study indicated that cyclosporin might be valuable in the treatment of patients with advanced rheumatoid arthritis, in whom other second line agents have failed.
The presumed mechanism of action of cyclosporin suggested clinical evaluation of its therapeutic potential in rheumatoid arthritis. Cyclosporin appears to block intercellular messages between inflammatory cells, probably by reducinf production of interleukin 2 and other lymphokines. Open trials have already suggested its dose dependent effectiveness in refractory rheumatoid arthritis but have also shown dose dependent toxicity.2l0 Moreover 17 Other criteria used to assess disease activity were pain evaluated on a visual analogue scale of 100 mm, duration of morning stiffness, number of swollen joints, Ritchie articular index,14 and daily corticosteroid intake.
Patients were followed up on an outpatient basis, twice during the first month, monthly for six months, and at three month intervals thereafter.
CLINICAL MONITORING
Blood pressure, heart rate, weight, and spontaneous patient complaints were recorded twice during the first month and then monthly.
LABORATORY ASSESSMENT
Laboratory assessment was made at the beginning of cyclosporin treatment and at each examination. It included complete blood count and differential platelet count, Westergren sedimentation rate, plasma creatinine concentration, electrolytes, serum magnesium concentration, plasma uric acid concentration and liver enzymes. Determination of rheumatoid factor titres by the Waaler-Rose test was carried out at entry and after two and four months. The presence of protein and blood in the urine was also assessed at each visit.
STATISTICAL ANALYSIS
Qualitative variables were compared by the x2 test, quantitative variables by the non-parametric MannWhitney U test for intergroup comparisons and by the non-parametric Wilcoxon test for intragroup comparisons. The threshold of significance adopted was 5% (two tailed). The treatment termination incidence curves were evaluated by the KaplanMeier method. Table 1 summarises the basic characteristics of the 49 patients. Seven patients withdrew from the study within the first four months owing to side effects. After the four month evaluation 15 other patients discontinued cyclosporin: seven for inefficacy, seven for inefficacy and side effects, and one for an unrelated event. Between the fourth and 12th month 10 more patients discontinued the drug: three for inefficacy, four for side effects, two for inefficacy and side effects, and one for an unrelated event. (Table 2 ). Moreover, in these patients there was a significant reduction in mean (SD) corticosteroid consumption (6.3 (4-2) mg/day at the beginning, 5-6 (3-6) mg/day after four months of cyclosporin treatment, and 4-4 (2.8) mg/day after one year; p=0-005).
Results

PATIENTS AND STUDY COURSE
Of the 11 patients who discontinued cyclosporin because of side effects, and in whom cyclosporin had been effective, recurrence of the disease was observed in eight after one to five weeks (mean: four weeks). Despite clinical improvement there was no significant change in rheumatoid factor titre. At entry 29 of the 42 patients who completed four months of treatment had a titre >1/16; 11 of these patients had a decrease in titre by at least two dilutions at four months, whereas four of the 13 patients who had a rheumatoid factor titre <1/16 at entry experienced an increase in this variable by at least two dilutions.
TOXICITY ASSESSMENT Table 3 summarises the side effects which occurred during the study as well as those which prompted discontinuation of cyclosporin. Figure 1 shows that although side effects occurred more often during the tOnly two patients withdrew from the study because of renal toxicity, but in nine others disease activity recurred after cyclosporin daily dosage reduction, and cyclosporin treatment was then discontinued.
first six months, renal toxicity was observed at eight months in two patients, and high blood pressure at the eighth and 11th month in two other patients. Among the side effects observed, renal toxicity, haematological toxicity, hypertension, and paraesthesia merit more details.
Renal toxicity A rise in plasma creatinine concentration of 50% over baseline or greater than 150 imoUl was observed in 24 of the 49 patients but prompted withdrawal of the drug in only two. Clinical characteristics of patients who developed renal toxicity were compared with those of patients who did not ( Plasma creatinine concentration changed from 80 (18) gmol/l (49 patients) before treatment to 106 (27) .tmoI/l (42 patients) after four months and to 97 (18) 1imol/l (17 patients) after one year.
In the 32 patients who had to discontinue cyclosporin before the end of this one year study the plasma creatinine concentration rose from 80 (18) iimol/l before treatment to 106 (27) imol/l at the end point of cyclosporin treatment and decreased to 88 (27) iimol/l one month after the discontinuation of the drug and to 80 (27) iimol/l after three months.
Plasma creatinine concentration returned to the basal value in all patients except two. In one of them the diagnosis of renal amyloidosis was confirmed by renal biopsy eight months after cyclosporin discontinuation and in the other systemic vasculitis developed three months after cyclosporin withdrawal.
Non-steroidal anti-inflammatory drugs were withdrawn during the trial while cyclosporin dosage remain unchanged in six patients. cyclosporin continuation in eight (median duration: one month).
Patients who complained of paraesthesia tended to have lower pretreatment serum magnesium concentrations (0-78 (0-04) v 0-81 (0.05) mmol/l, p=0057). Serum magnesium concentration decreased from 0-80 (0.05) mmol/l before treatment to 0-71 (0-07) mmol/l at week 2 (p<0.001) in all 49 patients. At this time serum magnesium concentration was lower in patients who then had or subsequently developed paraesthesia (0-67 (0.03) v 0-74 (0.08) mmol/l, p<0-02).
Hypertension
Despite medical treatment (nicardipine) hypertension resulted in withdrawal of five of the 11 patients in whom this side effect occurred. Moreover, two patients are still being treated 11 and 19 months after discontinuation of cyclosporin.
Some discrepancies were observed between the occurrence of hypertension and nephrotoxicity. Only seven patients developed both renal toxicity and hypertension after cyclosporin treatment. Thus renal toxicity did not occur in four of the 11 patients who developed hypertension, and hypertension did not occur in 17 of the 24 patients who showed renal toxicity.
LIFE TABLE ANALYSIS
Standard methods of life table analysis were applied to the 49 patients who entered the trial. Treatment termination was taken as the end point. Once generated, the total termination incidence curve was partitioned according to the main reason for treatment termination: inefficacy or adverse effects. Figure 2 shows the incidence of treatment termination for all reasons, the termination incidence curve for treatment failure, and treatment termination due to adverse effects. By four months, 43% of patients taking cyclosporin had stopped treatment and by one year 65% of patients had stopped.
Discussion
This one year open study confirmed cyclosporin efficacy in refractory rheumatoid arthritis. Moreover, the number of patients included in the study and the duration of treatment allowed better analysis of the benefit-to-risk ratio. 
RISKS
We observed the common side effects previously reported. 12 [18] [19] [20] Side effects were mostly observed during the first six months of treatment. The late occurrence of nephrotoxicity or hypertension, or both, in some patients, however, suggests that monthly clinical and biological monitoring is required indefinitely.
Renal toxicity of cyclosporin seems to be more frequent in patients with rheumatoid arthritis than in those with other autoimmune diseases.1921 These discrepancies may be explained by (a) the age of the patients with rheumatoid arthritis. Our data showed a higher incidence of renal toxicity in patients over 60 years old. Moreover, rheumatoid arthritis usually occurs during the fifth decade, which is later than the onset of other autoimmune diseases; (b) a previous renal disease either associated with rheumatoid disease itself22 or due to long term concomitant non-steroidal anti-inflammatory drug treatment. We observed a higher incidence of nephrotoxicity in patients with a plasma creatinine concentration above 90 imoIIl before cyclosporin treatment, but no influence of concomitant nonsteroidal anti-inflammatory drug treatment was shown. Despite this incidence of cyclosporin renal toxicity in patients with rheumatoid arthritis we never observed any irreversible deterioration of renal function in terms of plasma creatinine concentration. This might be explained by the close monitoring of the patients and the immediate modulation of the dosage in cases of renal toxicity.
Although we excluded patients with previous hypertension, this side effect was observed in 11 patients and warranted withdrawal of the drug in five of them. Our data showed a lower incidence of hypertension than that observed in Weinblatt's series (seven out of 10 patients studied), however,'0 suggesting that previous hypertension still has to be considered a contraindication to the initiation of cyclosporin treatment. The necessity for this precaution is emphasised by the fact that two patients in our series still need medical treatment for hypertension despite cyclosporin discontinuation. 
